Patents Assigned to CHILDREN'S HEALTHCARE OF ATLANTA, INC.
-
Patent number: 10016156Abstract: The present systems and methods provide a mechanism to assess viewer behavior, features of stimuli, and the interaction between viewer behavior and stimuli. The systems and methods described herein for quantifying blink response and blink inhibition provide moment-by-moments measurements of viewer engagement by measuring what is or is not engaging enough to warrant viewers' inhibition of blinking. The present disclosure describes measures of visual scanning, eye movements, blink data, and blink timing data to derive a measure of how engaged a person is with what he or she is looking at. Blink-related data as a measure of viewer engagement provides a mechanism for determining the most engaging spatial and temporal aspects of a stimulus.Type: GrantFiled: September 28, 2016Date of Patent: July 10, 2018Assignee: Children's Healthcare of Atlanta, Inc.Inventors: Ami Klin, Warren Jones, Sarah Shultz
-
Patent number: 9999666Abstract: In certain embodiments, this disclosure relates to conjugates comprising GM-CSF and IL-7 and uses related thereto, e.g., enhancing the adaptive immune system. Typically the GM-CSF and IL-7 are connected by a polymer linker, e.g., polypeptide. In certain embodiments, the disclosure relates to nucleic acids encoding these polypeptide conjugates, vectors comprising nucleic acid encoding polypeptide conjugates, and protein expression systems comprising these vectors such as infectious viral particles and host cells comprising such a nucleic acids.Type: GrantFiled: May 18, 2016Date of Patent: June 19, 2018Assignees: Emory University, Children's Healthcare of Atlanta, Inc.Inventors: Jacques Galipeau, Hsiang-Chuan Hsieh
-
Patent number: 9993575Abstract: Devices and methods relate to inducing or promoting hemostasis. The hemostasis device may include a support layer having a first surface and an opposing second surface. The device may include a layer, the layer disposed on the first surface. The layer may include a target surface configured to contact a target site. The layer may include a monolayer of about 100% graphene or may include laser-reduced graphene oxide. The device may include a sensor configured to measure a level of hemostasis of the target site. The methods relate to a method of manufacturing a hemostatic device including a monolayer of graphene or a layer of laser-reduced graphene oxide.Type: GrantFiled: March 4, 2013Date of Patent: June 12, 2018Assignees: Emory University, Children's Healthcare of Atlanta, Inc.Inventors: Wilbur A. Lam, Anton Sidorov, Zhigang Jlang
-
Patent number: 9872834Abstract: Liposomes of a size of less than 200 nanometers target tumors and preferentially deliver imipramine blue to tumors, including brain tumors such as gliomas. The imipramine blue decreases the invasiveness of the tumors, and inhibits tumor metastasis. The liposomes include cholesterol and chemically pure phospholipids that are essentially neutral and contain saturated fatty acids of between 16 and 18 carbon atoms, such as distearoylphosphatidyl choline, and can also include one or more pegylated phospholipids, such as DSPE-PEG.Type: GrantFiled: December 28, 2015Date of Patent: January 23, 2018Assignees: Emory University, Georgia Tech Research Corporation, Children's Healthcare of Atlanta, Inc.Inventors: Jennifer M. Munson, Ravi V. Bellamkonda, Jack L. Arbiser
-
Patent number: 9861307Abstract: The present systems and methods provide a mechanism to assess viewer behavior, features of stimuli, and the interaction between viewer behavior and stimuli. The systems and methods described herein for quantifying blink response and blink inhibition provide moment-by-moments measurements of viewer engagement by measuring what is or is not engaging enough to warrant viewers' inhibition of blinking. The present disclosure describes measures of visual scanning, eye movements, blink data, and blink timing data to derive a measure of how engaged a person is with what he or she is looking at. Blink-related data as a measure of viewer engagement provides a mechanism for determining the most engaging spatial and temporal aspects of a stimulus.Type: GrantFiled: September 28, 2016Date of Patent: January 9, 2018Assignee: Children's Healthcare of Atlanta, Inc.Inventors: Ami Klin, Warren Jones, Sarah Shultz
-
Publication number: 20170326256Abstract: Disclosed herein are recombinant viral vectors comprising a liver specific promotor in operable combination with a heterologous nucleic acid sequence encoding a protein, such as a clotting factor. Methods of treating a subject with a clotting disorder, such as hemophilia A or hemophilia B, are also provided.Type: ApplicationFiled: April 15, 2016Publication date: November 16, 2017Applicants: Emory University, Children's Healthcare of Atlanta, Inc.Inventors: Christopher B. Doering, H. Trent Spencer, Harrison C. Brown
-
Patent number: 9688959Abstract: In certain embodiments, this disclosure describes compositions comprising platelet lysates depleted of fibrinogen. In a further embodiment, the composition further comprises a cell culture medium component. This disclosure also provides a method for preparing the composition, comprising the steps of (a) lysing platelets providing a lysate; (b) removing cell debris; and (c) depleting fibrinogen by forming a removable mass by adding a metal salt such as calcium chloride. Furthermore, the disclosure also describes the product produced using said method.Type: GrantFiled: June 26, 2012Date of Patent: June 27, 2017Assignees: Emory University, Children's Healthcare of Atlanta, Inc.Inventors: Ian B. Copland, Jacques Galipeau
-
Patent number: 9683020Abstract: This disclosure relates to immunogenic compositions and methods of enhancing an immune response to an antigen. In certain embodiments, the disclosure relates to virus-like carries comprising a TLR5 agonist on the exterior without an antigen.Type: GrantFiled: July 31, 2012Date of Patent: June 20, 2017Assignees: Emory University, Children's Healthcare of Atlanta, Inc.Inventors: Richard W. Compans, Baozhong Wang, Fu Shi Quan
-
Patent number: 9676727Abstract: This disclosure relates to antiviral compounds disclosed herein and uses related thereto. In certain embodiments, the disclosure relates to pharmaceutical compositions. Typically, the pharmaceutical composition comprises a compound of formula I: or salt, prodrug, or ester thereof wherein X, Y, and R1 and R10 to R13 are described herein.Type: GrantFiled: July 7, 2016Date of Patent: June 13, 2017Assignees: Emory University, Children's Healthcare of Atlanta, Inc.Inventors: Richard K. Plemper, James P. Snyder, Aiming Sun
-
Patent number: 9657076Abstract: In certain embodiments, this disclosure relates to conjugates comprising GM-CSF and IL-4 and uses related thereto, e.g., enhancing the immune system. Typically the GM-CSF and IL-4 are connected by a linker. In certain embodiments, the disclosure relates to isolated nucleic acids encoding these polypeptide conjugates, vectors comprising nucleic acid encoding polypeptide conjugates, and protein expression systems comprising these vectors such as infectious viral particles and host cells comprising such a nucleic acids.Type: GrantFiled: October 23, 2013Date of Patent: May 23, 2017Assignees: Emory University, Children's Healthcare of Atlanta, Inc.Inventors: Jacques Galipeau, Jiusheng Deng
-
Publication number: 20170000841Abstract: The composition of the invention, liposomal glutathione, has been recently shown to have utility for having an antibiotic like effect on Klebsiella pneumonia cultures in vitro, and in vivo as demonstrated by efficacy in reducing by large multiples the presence of cultures of Klebsiella in rats in animal tests. Further, because the liposomal glutathione bolsters body defenses as well as appearing to have direct killing action, the propensity to create more and more resistant strains to antibiotic treatment is downgraded.Type: ApplicationFiled: August 19, 2016Publication date: January 5, 2017Applicants: Emory University, YOUR ENERGY SYSTEMS, LLC, Children's Healthcare of Atlanta, Inc.Inventors: Lou Ann Brown, Frederick Timothy Guilford
-
Patent number: 9510752Abstract: The present systems and methods provide a mechanism to assess viewer behavior, features of stimuli, and the interaction between viewer behavior and stimuli. The systems and methods described herein for quantifying blink response and blink inhibition provide moment-by-moments measurements of viewer engagement by measuring what is or is not engaging enough to warrant viewers' inhibition of blinking. The present disclosure describes measures of visual scanning, eye movements, blink data, and blink timing data to derive a measure of how engaged a person is with what he or she is looking at. Blink-related data as a measure of viewer engagement provides a mechanism for determining the most engaging spatial and temporal aspects of a stimulus.Type: GrantFiled: December 11, 2013Date of Patent: December 6, 2016Assignee: Children's Healthcare of Atlanta, Inc.Inventors: Ami Klin, Warren Jones, Sarah Shultz
-
Patent number: 9499489Abstract: This disclosure relates to antiviral compounds disclosed herein and uses related thereto. In certain embodiments, the disclosure relates to pharmaceutical compositions. Typically, the pharmaceutical composition comprises a compound of formula I: Formula I, or salt, prodrug, or ester thereof wherein X, Y, and R1 and R10 to R13 are described herein.Type: GrantFiled: October 24, 2012Date of Patent: November 22, 2016Assignees: Emory University, Children's Healthcare of Atlanta, Inc.Inventors: Richard K. Plemper, James P. Snyder, Aiming Sun
-
Publication number: 20160262613Abstract: Systems, devices, and methods are described for assessing the risk of developmental, cognitive, social, or mental abilities or disabilities in very young patients (e.g., in the first 2-6 months of life). Generally, the decline in visual fixation of a subject over time with respect to certain dynamic stimuli provides a marker of possible abilities or disabilities (such as ASD). The visual fixation of the subject is identified, monitored, and tracked over time through repeated eye tracking sessions, and data relating to the visual fixation is then analyzed to determine a possible increased risk certain conditions in the subject. A change in visual fixation as compared to similar visual fixation data of typically-developing subjects or to a subject's own, prior visual fixation data provides an indication of a developmental, cognitive, or mental ability or disability.Type: ApplicationFiled: September 10, 2014Publication date: September 15, 2016Applicant: Children's Healthcare of Atlanta, Inc.Inventors: Ami KLIN, Warren JONES
-
Publication number: 20160199337Abstract: This disclosure relates to nutritional formulas and uses for treating or preventing a gastrointestinal condition and/or motor-planning speech and/or coordinator difficulties. In certain embodiments, this disclosure relates to a nutritional formula comprising medium 5 chain fatty acids, or esters thereof (such as and tri-, di-, mono-glycerides, or alkyl esters), unsaturated fatty acids, and a vitamin E and optionally other nutrients. In certain embodiments, any of the compounds or nutrients may be in alternative salt forms.Type: ApplicationFiled: September 4, 2014Publication date: July 14, 2016Applicant: Children's Healthcare of Atlanta, Inc.Inventor: Claudia R. Morris
-
Patent number: 9375465Abstract: In certain embodiments, this disclosure relates to conjugates comprising GM-CSF and IL-7 and uses related thereto, e.g., enhancing the adaptive immune system. Typically the GM-CSF and IL-7 are connected by a polymer linker, e.g., polypeptide. In certain embodiments, the disclosure relates to nucleic acids encoding these polypeptide conjugates, vectors comprising nucleic acid encoding polypeptide conjugates, and protein expression systems comprising these vectors such as infectious viral particles and host cells comprising such a nucleic acids.Type: GrantFiled: November 13, 2012Date of Patent: June 28, 2016Assignees: Emory University, Children's Healthcare of Atlanta, Inc.Inventors: Jacques Galipeau, Hsiang-Chuan Hsieh
-
Patent number: 9365523Abstract: This disclosure relates to antiviral compounds disclosed herein and uses related thereto. In certain embodiments, the disclosure relates to pharmaceutical compositions comprising 2-((benzo[d]imidazol-2-yl)thio)-N-phenylpropanamide derivatives, N-phenyl-2-((1-phenyl-benzo[d]imidazol-2-yl)thio)propanamide derivatives, or 2-((benzo[d]imidazol-2-yl)thio)-N-(2-chloro-4-methylphenyl)propanamide derivatives. The derivatives may be substituted with one or more substituents. Typically, the pharmaceutical composition comprises a compound of Formula (I), or salt, prodrug, or ester thereof wherein X, Y, and R1 to R7 are described herein.Type: GrantFiled: March 28, 2012Date of Patent: June 14, 2016Assignees: Emory University, Children's Healthcare of Atlanta, Inc.Inventors: Richard K. Plemper, James P. Snyder, Aiming Sun, John M. Ndungu, Jeong-Joong Yoon
-
TREATMENT OF MULTIPLE EVOLVING BACTERIAL RESISTANCE DISEASES WITH LIPOSOMALLY FORMULATED GLUTATHIONE
Publication number: 20160158308Abstract: The invention proposes routine treatment of patients, particularly those admitted to an ICU, with Vitamin D and liposomal glutathione for prophylaxis and treatment against Group B Streptococcus and Carbapenem-resistant enterobacteriaceae, and biomarkers to measure effectiveness of treatment. Further, because the method of treatment bolsters body defenses as well as appearing to have direct killing action, the propensity to create more and more antibiotic- and/or carbapenem resistant strains is downgraded.Type: ApplicationFiled: August 14, 2014Publication date: June 9, 2016Applicants: EMORY UNIVERSITY, CHILDREN'S HEALTHCARE OF ATLANTA, INC., YOUR ENERGY SYSTEMS, LLCInventors: Lou Ann Brown, Frederick Timothy Guilford -
Patent number: 9265416Abstract: Systems, devices, and methods are described for the assessment, screening, monitoring, or diagnosis of developmental or cognitive conditions, including autism spectrum disorders (ASD) by analysis of eye tracking data generated from feedback received as a result of display of specific predetermined visual stimuli to a subject or patient. Subsequent to a calibration phase, a testing procedure is performed by presenting predetermined stimuli (e.g., videos) to a subject via a display device. Eye tracking data (from the subject moving his or her eyes in response to predetermined movies or other visual stimuli) are collected. During the data collection period, the system periodically presents targets to reflexively elicit the subject's gaze. These data are used to later verify accuracy. Analysis of the subject's viewing patterns during these stimuli is used for the assessment, screening, monitoring, or diagnosis of developmental or cognitive conditions such as ASD.Type: GrantFiled: March 11, 2014Date of Patent: February 23, 2016Assignee: Children's Healthcare of Atlanta, Inc.Inventors: Ami Klin, Warren Jones, Peter Lewis
-
Patent number: 9220682Abstract: Liposomes of a size of less than 200 nanometers target tumors and preferentially deliver imipramine blue to tumors, including brain tumors such as gliomas. The imipramine blue decreases the invasiveness of the tumors, and inhibits tumor metastasis. The liposomes include cholesterol and chemically pure phospholipids that are essentially neutral and contain saturated fatty acids of between 16 and 18 carbon atoms, such as distearoylphosphatidyl choline, and can also include one or more pegylated phospholipids, such as DSPE-PEG.Type: GrantFiled: April 21, 2010Date of Patent: December 29, 2015Assignees: Emory University, Georgia Tech Research Corporation, Children's Healthcare of Atlanta, Inc.Inventors: Jennifer M. Munson, Ravi V. Bellamkonda, Jack L. Arbiser